Long-term outcome of ATG vs. Basiliximab induction

Ulrich, Frank; Niedźwiecki, Sebastian; Pascher, Andreas; Köhler, Sven; Weiß, Sascha; Fikatas, Panagiotis; Schumacher, Guido; May, G.; Reinke, Petra; Neuhaus, P.; Tullius, Stefan G.; Pratschke, Johann

doi:10.1111/j.1365-2362.2011.02490.x

Cited by 28 publications

(18 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chapal et al also found five explicative variables that contributed significantly to DGF prediction, and demonstrated that risk of DGF was reduced 1.73-fold in patients with ATG [6]. Other studies also demonstrated significantly lower rates of DGF in ATG-induced DCD recipients [24][25][26]. Our results demonstrated that ATG as induction therapy in DBCD donation could reduce the risk of DGF by more than half.…”

Section: Discussionsupporting

confidence: 59%

New Factors Predicting Delayed Graft Function: a Multi-Center Cohort Study of Kidney Donation After Brain Death Followed by Circulatory Death

Sun

Huang

Zhou

et al. 2018

Kidney Blood Press Res

View full text Add to dashboard Cite

Background/Aims: Delayed graft function (DGF) is a common complication following kidney transplantation adversely affecting graft outcomes. Donation after brain death followed by circulatory death (DBCD), a novel donation pattern, is expected to correlate with high incidence of DGF. However, little information is available about factors associated with DGF in DBCD. Methods: A total of 383 kidney transplants from DBCD donation in three institutions were enrolled. Associations of DGF with the clinical characteristics of recipients and donors were quantified. Results: In this retrospective multi-center study, the incidence of DGF was 19.3%. Lower incidence of DGF was found in recipients for whom antithymocyte globulin was used for induction (p < 0.05), which was an independent protective factor against DGF (odds ratio [OR] = 0.48; 95% CI 0.27-0.86). Two novel explicative variables were recognized as independent risk factors, including use of vasoactive drugs (OR = 3.15; 95% CI 1.39-7.14) and cardiopulmonary resuscitation (OR = 2.51; 95% CI 1.05-6.00), which contributed significantly to increased risk of DGF (p < 0.05). Prolonged warm ischemia time (> 18 min; OR = 2.42; 95% CI 1.36-4.32), was also predictive of DGF in DBCD. A prediction model was developed and achieved an area under the curve of 0.89 in predicting DGF when combined with reported parameters. Conclusion: The novel factors, confirmed for the first time in our study, will help to improve risk prediction of DGF and to determine optimal interventions to prevent DGF in clinical practice.

show abstract

Section: Discussionsupporting

confidence: 59%

New Factors Predicting Delayed Graft Function: a Multi-Center Cohort Study of Kidney Donation After Brain Death Followed by Circulatory Death

Sun

Huang

Zhou

et al. 2018

Kidney Blood Press Res

View full text Add to dashboard Cite

show abstract

“…Basiliximab had low acute rejection rates similar to those achieved by rATG; however, it had a better safety profile, with no increase in malignancies, infections, or deaths [29] . Another study showed that the 6-year patient and graft survival in the rATG group was not significantly higher than that compared to basiliximab (91.7 vs. 85% and 89.7 vs. 83.6%, respectively); however, cytomegalovirus infections were more prevalent in the rATG group (22 vs. 5%, p = 0.05) and so was the incidence of hematological complications [30] .…”

Section: Discussionmentioning

confidence: 99%

Poor Outcomes in Elderly Kidney Transplant Recipients Receiving Alemtuzumab Induction

et al. 2011

View full text Add to dashboard Cite

justing for baseline differences, induction with alemtuzumab was associated with an increased risk of graft loss and death, with an adjusted hazard ratio (AHR) of 1.26 (95% CI 1.08-1.48). Risk was also present at other age cutoffs [age 1 60 (AHR 1.16; 95% CI 1.03-1.31; p = 0.014), age 1 70 (AHR 1.43; 95% CI 1.13-1.81; p = 0.003) and age 1 75 (AHR 1.68; 95% CI 1.07-2.63; p = 0.024)]. Conclusions: In the elderly, alemtuzumab is associated with an escalating risk of death and graft loss in recipients of kidney transplantations.

show abstract

“…[24][25][26][27] In solid organ transplantation, ATG treatment effectively prevents rejection and is used as induction therapy and as for overcoming acute rejection episodes. 25,28 In this experiment, ATG donor preconditioning was able to reduce BD-triggered inflammation in donors and recipients in a clinically applicable setting.…”

Section: Figurementioning

confidence: 95%

Graft-specific immune cells communicate inflammatory immune responses after brain death

Floerchinger¹,

Ge²,

Lee³

et al. 2012

The Journal of Heart and Lung Transplantation

Self Cite

View full text Add to dashboard Cite

Long-term outcome of ATG vs. Basiliximab induction

Abstract: ATG induction was associated with an improved (but n.s.) trend in patient and graft survival. Patients induced with ATG had a higher rate of CMV infections and haematological complications.

Cited by 28 publications

References 38 publications

New Factors Predicting Delayed Graft Function: a Multi-Center Cohort Study of Kidney Donation After Brain Death Followed by Circulatory Death

New Factors Predicting Delayed Graft Function: a Multi-Center Cohort Study of Kidney Donation After Brain Death Followed by Circulatory Death

Poor Outcomes in Elderly Kidney Transplant Recipients Receiving Alemtuzumab Induction

Graft-specific immune cells communicate inflammatory immune responses after brain death

Contact Info

Product

Resources

About